Low-Field and Portable MRI: What Radiographers Need to Know

Key takeaway: Low-field MRI can expand access to imaging, and some ultra-low-field scanners can be moved directly to the bedside. But lower field strength and portability are not the same thing. Imaging performance, safety precautions and the FDA-cleared indications differ markedly by system. Point-of-care MRI can complement conventional MRI; it does not automatically replace 1.5 T or 3 T examinations or emergency CT pathways. [1, 3, 5, 6]

Magnetic resonance imaging (MRI) uses magnetic fields and radiofrequency pulses to produce images without ionizing radiation. Conventional clinical MRI commonly operates at 1.5 tesla (T) or 3 T. Renewed interest in lower-field systems comes from improvements in hardware, image reconstruction, cost and access—not from any claim that low-field imaging performs equally well for every clinical question. [1–3]

Low-field, ultra-low-field and portable: know the difference

These labels are not universally standardized. Some reviews use low-field broadly for any system below 1.5 T, while other expert publications reserve it for a narrower range and call 0.5–1 T scanners mid-field. In this article, lower-field MRI refers broadly to systems below 1.5 T, and ultra-low-field/very-low-field bedside MRI refers to the approximate 0.064 T class. These are practical descriptions rather than regulatory definitions. [1, 3]

• Field strength describes the static magnetic field, measured in tesla. Two lower-field scanners can be designed for completely different clinical tasks.
• Portability describes whether equipment can be relocated to where the patient is. A 0.064 T bedside brain scanner may be wheelable; a 0.55 T whole-body system or an office-based prostate-intervention system is not automatically bedside portable.
• Point-of-care means imaging near the location of treatment. It does not necessarily mean the scanner moves between rooms.

The goal is to match the system to the clinical question—not to label all lower-field machines as interchangeable.

Why field strength affects image quality

Signal-to-noise ratio (SNR) is a major MRI trade-off. Holding other factors constant, SNR generally increases with the static field strength; it also improves approximately with the square root of acquisition time. At lower field strength, technologists may need to trade spatial resolution, scan time, coil design, bandwidth or reconstruction settings to obtain usable images. The simple proportional relationship is a teaching approximation, not a guarantee of identical performance between scanner designs. [1, 2]

Two practical differences are especially important:

• Fat suppression: The water–fat resonance difference is approximately 220–225 Hz at 1.5 T but only 80–82 Hz at 0.55 T. Narrower separation can make conventional frequency-selective fat suppression less robust. Dixon-type water–fat separation can help in suitable protocols, although it may require different echo timings or acquisition times. [1, 2]
• Susceptibility and metal artifacts: Many susceptibility-related distortions decrease at lower field strength. This can improve visualization around some metallic implants, but it does not establish that the implant itself is MRI-safe. [1, 2, 8]

Some low-field systems also require less power or infrastructure and may generate less acoustic noise. However, costs, noise, specific absorption rate (SAR) and safety characteristics depend on the actual scanner and sequence—not on field strength alone. [1, 8]

Field strength and mobility at a glance

Important: This is a comparison of examples, not a complete catalogue. The Promaxo original FDA documentation lists a field range of 0.058–0.074 T, describes fixed installation, and requires a prior 3 T MR image for its procedural-guidance workflow. [1, 10, 11]

Cost: One 2025 review cites an estimate that some 0.55 T systems may cost roughly 40–50% of a conventional 1.5 T system. That is an estimate drawn from the literature, not a current quoted price or a universal savings rate. Capital, siting, staffing, service, training and protocol requirements can change the total cost of ownership. [1]

What the published clinical evidence actually shows

Results must be interpreted according to the population, scanner, comparator and outcome measured. Agreement in whether an image contains an abnormality is not the same as sensitivity for every disease, and a study on one machine cannot validate an entire field-strength category.

How to interpret older positive stroke studies: A smaller study cited in the 2025 review detected 45 of 50 known infarct cases at 0.064 T and missed five small lesions. This result is genuine, but the 2026 meta-analysis gives a broader and more cautious estimate of performance. Stroke volume agreement, lesion detection and reliable exclusion of acute stroke are three different endpoints. [1, 6]

Where lower-field MRI may be useful

• Intensive care and emergency departments: Bedside brain imaging may avoid transport in selected patients who are difficult or unsafe to move. The decision depends on clinical urgency, device compatibility, staffing and whether conventional CT or MRI is required. It should not delay established acute-stroke assessment or treatment. [1, 5, 6]
• Neonatal care: Dedicated neonatal scanners can image an infant near the care environment. However, neonatal 1 T systems and 0.064 T mobile brain scanners have different designs, restrictions and evidence. Not every newborn, implant or clinical question is eligible. [1, 12]
• Outpatient neurology: Portable structural brain MRI may improve access and patient experience in selected clinics. The 125-person concordance study was encouraging, but small-lesion detection and disease-specific follow-up still need careful assessment. [4, 5]
• Musculoskeletal imaging: Installed lower-field systems can be useful for selected joint examinations; smaller susceptibility artifacts may benefit imaging near orthopedic hardware. Thin cartilage abnormalities and other subtle findings may still require higher-resolution protocols or conventional MRI. [1, 2]
• Interventional imaging: Some compact systems support specific procedures. Promaxo is intended for guidance of prostatic lesion targeting in trained hands; its original FDA documentation explicitly states that its own images are not intended for diagnostic purposes and that a prior 3 T MRI study is required. [10, 11]

Clinical rule: Ask whether this scanner and protocol can answer this patient's question. A positive finding may be actionable while a negative or indeterminate portable MRI examination may still need conventional imaging.

FDA clearance: understand the exact intended use

The following are representative U.S. FDA 510(k) records, verified October 11, 2026. A 510(k) clearance is a substantial-equivalence determination for specified intended uses. It is not proof of diagnostic superiority, and multiple clearances for a product family do not mean multiple separate scanner models.

U.S. versus Canada: FDA clearance does not establish a device's authorization for sale in Canada. Canadian medical-device licences should be checked separately in Health Canada's Medical Devices Active Licence Listing (MDALL). Canadian licence status for the named systems was not independently established in this article. [13]

What changes for radiographers and MRI technologists?

1. Screening and controlled access still matter

Low-field does not mean implant-safe. Ferromagnetic forces may often be lower, but RF-induced heating of conductive implants depends on implant length, configuration, placement, sequence and scanner. In a published deep-brain-stimulation implant study, heating at 0.55 T was sometimes comparable to or greater than at 1.5 T. A pacemaker or neurostimulator must be identified and assessed against the manufacturer’s exact MR conditions and the site's approved policy, not simply the field strength printed on the scanner. [8, 9]

Portable scanner placement changes the workflow: personnel, visitors, neighboring equipment and the moving scanner must still be managed according to the system-specific safety plan. Follow the current ACR Manual on MR Safety, applicable local protocols and medical-physics guidance. [9]

2. Protocols are not interchangeable

Check coil fit, anatomical coverage, motion, SNR, sequence limitations and acquisition time. Lower-field systems may need optimized water–fat separation and careful assessment of diffusion-weighted imaging (DWI). Image quality can change with hardware and software revisions, so findings from one generation cannot automatically be transferred to another. [1–3]

3. AI reconstruction still requires critical review

Standard denoising and more generative image-synthesis systems are not identical. Generative reconstruction can produce plausible-looking details that were not reliably measured. Know which processing was used, review original data when available and follow approved diagnostic workflows. [7]

4. Escalate negative or unclear studies appropriately

An MRI examination is useful only if it can answer the clinical question. When acute stroke, a small lesion or another condition remains strongly suspected, a negative portable scan may not exclude it. Escalation to conventional MRI, CT or other imaging must follow clinical pathways and the reporting physician's decision. [5, 6]

Common misconceptions: error-to-correction

1. “Low field means implants are automatically safe.” Correction: Every implant and scanning condition needs verification. Some conductive implants can experience significant RF heating even at 0.55 T. [8, 9]
2. “Portable means the usual MRI safety rules no longer apply.” Correction: The magnet remains active; controlled access, screening and system-specific precautions remain essential. [9]
3. “A bedside MRI can rule out any acute stroke.” Correction: The 2026 meta-analysis found pooled sensitivity of 73.3% in the six comparative studies. A negative portable study cannot independently exclude stroke when clinical suspicion persists. [6]
4. “A better-looking AI image is necessarily more accurate.” Correction: Improved apparent detail does not eliminate the possibility of hallucinated features. Clinical validation is needed. [7]

Self-check

1. A patient with a pacemaker is referred for a 0.064 T portable MRI. What should you do?

A. Assume the pacemaker is safe because the field is low.
B. Identify the device and verify its exact MR conditions and local approval process before scanning.
C. Assume all pacemakers are prohibited and skip identification.
D. Skip controlled-access precautions because the scanner is portable.

Correct answer: B. A is unsafe; lower field does not prove compatibility. C is also incorrect because device-specific MR Conditional pathways exist. D overlooks residual magnetic-field hazards. [8, 9]

2. Which consequence follows from a decrease in static magnetic field strength?

A. Every low-field scanner becomes wheelable.
B. The fat–water frequency separation becomes larger.
C. The fat–water frequency separation becomes smaller.
D. Susceptibility artifacts always increase.

Correct answer: C. Fat–water separation is about 225 Hz at 1.5 T and 82 Hz at 0.55 T; spectral fat-suppression approaches may require adjustment. Portability is a separate system-design feature, and susceptibility artifacts often decrease rather than increase. [2]

3. A 0.064 T portable scan is negative, but the treating team still strongly suspects acute ischemic stroke. What is the appropriate interpretation?

A. Stroke has been ruled out.
B. Portable MRI has the same sensitivity as 3 T MRI.
C. The negative finding does not exclude acute stroke; follow the established emergency imaging pathway.
D. AI enhancement alone will always settle the diagnosis.

Correct answer: C. Smaller infarcts may be missed, and the comparative evidence does not support portable MRI as a standalone rule-out test. [6]

What to watch next

Research is exploring lighter permanent-magnet arrangements, improved coils, new portable workflows, accelerated acquisition and AI reconstruction. These are promising developments, not proof that prototype systems or unvalidated image enhancement are ready for routine diagnosis. Lower-field MRI is clinically available for selected uses and continues to evolve. [1, 3, 5, 7]

Learn next

• MRI Physics for Technologists
• CT vs MRI: Key Differences & When to Use
• Photon-Counting CT: What Radiographers Need to Know
• Practice Test Center

References and primary sources

1. Kravchenko D, Hagar MT, Vecsey-Nagy M, et al. Low-field and portable MRI technology: advancements and innovations. European Radiology Experimental. 2025;9:103. doi:10.1186/s41747-025-00638-2. (Narrative review; some estimates and smaller studies are reported through this review.)
2. Low-Field-Strength Body MRI: Challenges and Opportunities at 0.55 T. RadioGraphics. doi:10.1148/rg.230073. (Physics, fat suppression and artifacts.)
3. Campbell-Washburn AE, et al. Low-field MRI: A report on the 2022 ISMRM workshop. Magnetic Resonance in Medicine. 2023. doi:10.1002/mrm.29743. (Nomenclature and clinical positioning.)
4. Mechtler L, Ansari SA, Derakhshan J, et al. Portable Ultra-Low-Field MRI in Outpatient Neurology: An Examination of Clinical Performance and Patient Experience. Journal of Neuroimaging. 2026;36(4):e70143. doi:10.1111/jon.70143; PMID 42627086. (Industry-sponsored, with author financial relationships.)
5. Okar SV, Thommana AA, Donnay C, et al. Portable Ultra-Low-Field MRI in Neurologic Diseases: Current Status and Potential in Clinical Practice, Research, and Trials. Neurology. Published online October 7, 2026. doi:10.1212/WNL.0000000000218518; PMID 42842854. (Narrative review; journal issue dated November 10, 2026.)
6. Pence MC, Elek A, Bilgin C, et al. Diagnostic Accuracy of Portable Low- and Ultra-Low-Field MRI for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. American Journal of Neuroradiology. Published online July 16, 2026. doi:10.3174/ajnr.A9532; PMID 42463301.
7. Islam KT, Dayarathna S, Zhong S, et al. SynPoC: a high-quality generative diffusion model for transforming ultra-low-field point-of-care MRI using high-field MRI representations. Scientific Reports. 2026;16:3285. doi:10.1038/s41598-025-33162-9; PMID 41580445.
8. Comparative study of radiofrequency heating in deep brain stimulation devices during MRI at 1.5 T and 0.55 T: Challenging the assumption of safety at low field strengths. PMID 40294129. (Experimental implant-heating study.)
9. American College of Radiology. ACR Manual on MR Safety (2026). ACR MR Safety resources.
10. U.S. Food and Drug Administration. Promaxo MRI System, 510(k) K202518 (March 3, 2021). FDA clearance record.
11. U.S. Food and Drug Administration. Promaxo 510(k) summary, indications for use and device characteristics. FDA K202518 summary (PDF).
12. U.S. Food and Drug Administration. FDA clears first neonatal MRI device. FDA announcement; K170978.
13. Health Canada. Medical Devices Active Licence Listing (MDALL). Official active-licence search.

Additional U.S. FDA clearances are linked directly in the regulatory table; that table is selective, not an exhaustive device-registry export.